ArticleJournal of bone oncology2023

A randomized trial comparing LY01011, biosimilar candidate, with the reference product denosumab (Xgeva®) in healthy Chinese subjects.

Yanhua Ding et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.